TNFSF10 and Miyoshi myopathy: Because TRAIL is not cytotoxic to normal tissues unlike Fas ligand and TNF-α, TRAIL-mediated immunotherapy is tumor-specific, and regarded as an attractive maneuver against various cancers including MM [5], [6], [7].